Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Dr. Joseph J. Eiden Jr.

Head of Medical Affairs

Mr. David V. Elkins

Executive Vice President & Chief Financial Officer

Ms. Sandra  Leung Esq.

Executive Vice President & General Counsel

Mr. Samit  Hirawat M.D.

Executive Vice President, Chief Medical Officer & Head of Development

Mr. Adam  Lenkowsky

Executive Vice President, Chief Commercialization Officer & Head of U.S. Oncology

Name	Market cap
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
PT Kalbe Farma Tbk.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
Astellas Pharma Inc.	0M
NGL Fine-Chem Limited	0M
Orion Oyj	0M
Chugai Pharmaceutical Co., Ltd.	0M
Novartis AG	0M

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company Competitors List

Main competitors